Company Overview of ARCA biopharma, Inc.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
11080 CirclePoint Road
Westminster, CO 80020
Key Executives for ARCA biopharma, Inc.
Total Annual Compensation: $389.4K
Senior Vice President
Total Annual Compensation: $323.6K
Compensation as of Fiscal Year 2013.
ARCA biopharma, Inc. Key Developments
ARCA biopharma, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 11:30 AM
Dec 19 14
ARCA biopharma, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 11:30 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.
ARCA biopharma, Inc. Announces Activation of First Canadian Genetic-AF Clinical Trial Site
Dec 11 14
ARCA biopharma, Inc. announced the activation of the first GENETIC-AF clinical trial site in Canada. The site activation follows on the August 2014 acceptance by Health Canada of the company's Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation (AF). This site brings the total current number of active trial sites to thirty-three. ARCA plans to activate a total of approximately 60 clinical trial sites in the United States and Canada for the Phase 2B portion of the trial. ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is now enrolling patients in the United States and Canada. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation.
ARCA biopharma, Inc. Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola
Dec 10 14
ARCA biopharma, Inc. announced that the U.S. Food and Drug Administration(FDA) Office of Orphan Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus. The drug candidate has previously demonstrated post-exposure efficacy in non-human primate models of Ebola hemorrhagic fever virus (HFV). rNAPc2 was originally developed as a cardiovascular therapy for thrombosis and other indications. As a result, it has an extensive human clinical record, and has been safely tested in over 700 human patients in nine Phase 1 and 2 clinical trials for cardiovascular disease.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|